Skip to Content



View full screen / Print PDF » Download PDF ⇩
Powder for solution for injection or infusion
Ceftazidime 1 g, Powder for solution for injection or infusion
Read all of this leaflet carefully before you start using this medicine because it
contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor.
• If you get any side effects, talk to your doctor. This includes any possible side
effects not listed in this leaflet.
What is in this leaflet
1. What Ceftazidime is and what it is used for
2. What you need to know before you are given Ceftazidime
3. How Ceftazidime is given
4. Possible side effects
5. How to store Ceftazidime
6. Contents of the pack and other information
1. What Ceftazidime is and what it is used for
Ceftazidime contains the active substance Ceftazidime.
Ceftazidime is an antibiotic used in adults and children (including newborn babies).
It works by killing bacteria that cause infections. It belongs to a group of medicines
called cephalosporins.
Ceftazidime is used to treat severe bacterial infections of:
• the lungs or chest
• the lungs and bronchi in patients suffering from cystic fibrosis
• the brain (meningitis)
• the ear
• the urinary tract
• the skin and soft tissues
• the abdomen and abdominal wall (peritonitis)
• the bones and joints.
Ceftazidime can also be used:
• to prevent infections during prostate surgery in men
• to treat patients with low white blood cell counts (neutropenia) who have a fever
due to a bacterial infection
2. What you need to know before you are given Ceftazidime
You must not be given Ceftazidime
• if you are allergic (hypersensitive) to ceftazidime or any other ingredients of this
medicine (listed in section 6).
• if you have had a severe allergic reaction to any other antibiotic (penicillins,
monobactams and carbapenems) as you may also be allergic to Ceftazidime.
Tell your doctor before you start on Ceftazidime if you think that this applies to you.
You must not be given Ceftazidime then.

Warnings and precautions
You must look out for certain symptoms such as allergic reactions, nervous system
disorders and gastrointestinal disorders such as diarrhoea while you are being
given Ceftazidime (see section 4). This will reduce the risk of possible problems.
If you have had an allergic reaction to other antibiotics you may also be allergic to
If you need a blood or urine test
Ceftazidime can affect the results of urine test for sugar and a blood test known as
the Coombs test.
Other medicines and Ceftazidime
Tell your doctor if you are taking, have recently taken or might take any other
You shouldn’t be given Ceftazidime without talking to your doctor if you are also
• an antibiotic called chloramphenicol
• a type antibiotic called aminoglycosides e.g., gentamicin, tobramycin
• water tablets called furosemide
Pregnancy, breast-feeding and fertility
Tell your doctor before you are given Ceftazidime:
• If you are pregnant, think you might be pregnant or are planning to have a baby
• If you are breastfeeding
Your doctor will consider the benefit of treating you with Ceftazidime against the
risk to your baby.
Driving and using machines
Ceftazidime can cause side effects that affect your ability to drive, such as dizziness.
Don’t drive or use machines unless you are sure you’re not affected.
Ceftazidime contains sodium
You need to take this into account if you are on a controlled sodium diet.
1 g: This medicinal product contains 51.2 mg (2.23 mmol) of sodium per dose.
3. How Ceftazidime is given
Ceftazidime is usually given by a doctor or nurse. It can be given as a drip
(intravenous infusion) or as an injection directly into a vein or into a muscle.
Ceftazidime is reconstituted by the doctor, pharmacist or nurse using water for
injections or a suitable infusion fluid.
The usual dose
The correct dose of Ceftazidime for you will be decided by your doctor and depends
on: the severity and type of infection; whether you are on any other antibiotics; your
weight and age; how well your kidneys are working.
Newborn babies (0-2 months)
For every 1 kg the baby weighs, they’ll be given 25 to 60 mg Ceftazidime per day
divided in two doses.
Babies (over 2 months) and children who weigh less than 40 kg
For every 1 kg the baby or child weighs, they’ll be given 100 to 150 mg of Ceftazidime
per day divided in three doses. Maximum 6 g per day.
Adults and adolescents who weigh 40 kg or more
1 to 2 g of Ceftazidime three times daily. Maximum of 9 g per day.

Routes of administration:
Only for 1 g, Powder for solution for injection or infusion:
Intravenous use,
Intramuscular use (in exceptional clinical situations)
Only for 2 g and 3 g, Powder for solution for injection or infusion:
Intravenous use
Method of administration:
Ceftazidime may be given intravenously by slow bolus injection over a few minutes.
Ceftazidime 1 g Powder for solution for injection or infusion may be given by deep
intramuscular injection into a large muscle mass, such as the upper outer quadrant
of the gluteus maximum or lateral part of the thigh. The intramuscular method of
administration is reserved to exceptional clinical situations and should undergo a
risk-benefit assessment.
Ceftazidime 1 g, 2 g and 3 g Powder for solution for injection or infusion may be
given intravenously by infusion over 15-30 minutes.
Ceftazidime should not be mixed with solutions with a pH above 7.5 for example
sodium bicarbonate solution for injection. Ceftazidime and aminoglycosides should
not be mixed in the solution for infusion because of the risk of precipitation.

Cannulae and catheters for intravenous use should be flushed with physiological
salt-solution between administrations of ceftazidime and vancomycin to avoid
Instructions for constitution
See table for addition volumes and solution concentrations, which may be useful
when fractional doses are required.
Vial size

1 g Powder for solution for
injection or infusion
1 g

Intravenous bolus

Intravenous infusion
2 g Powder for solution for
injection or infusion
Intravenous bolus

Intravenous infusion
3 g Powder for solution for
injection or infusion
3 g
Intravenous bolus

Intravenous infusion

Amount of diluent
to be added (ml)

*Note: Addition should be in two stages.

concentration (mg/ml)

3 ml
10 ml
50 ml*


10 ml
50 ml*


15 ml
75 ml*


Patients over 65
The daily dose should not normally exceed 3 g per day, especially if you are over
80 years of age.
Patients with kidney problems
You may be given a different dose to the usual dose. The doctor will decide how
much Ceftazidime you will need, depending on the severity of the kidney disease.
Your doctor will check you closely and you may have more regular kidney function
If you are given more Ceftazidime than you should
If you are accidentally given more than your prescribed dose, contact your doctor
or nearest hospital straight away.
If you forget to be given Ceftazidime
If you miss an injection, you should have it as soon as possible. However, if it is
almost time for your next injection, the missed injection will be skipped. Don’t take a
double dose (two injections at the same time) to make up for a missed dose.
If you stop using Ceftazidime
Don’t stop taking Ceftazidime unless your doctor tells you to.
If you have further questions on the use of this medicine, ask your doctor or nurse.
4. Possible side effects
Like all medicines this medicine can cause side effects, although not everybody
gets them.
Following serious side effects have occurred in a small number of people but their
exact frequency is unknown:
• Severe allergic reaction. Signs include raised and itchy rash, swelling,
sometimes of the face or mouth causing difficulty in breathing.
• Skin rash, which may blister, and looks like small targets (central dark spot
surrounded by a paler area, with a dark ring around the edge).
• A widespread rash with blisters and peeling skin. (These may be signs of
Stevens-Johnson syndrome or toxic epidermal necrolysis).
• Nervous system disorders: tremors, fits and, in some cases coma. These have
occurred in people when the dose they are given is too high, particularly in
people with kidney disease.
Contact a doctor or nurse immediately if you get any of these symptoms.
Other side effects
Common: may affect up to 1 in 10 people:
• diarrhoea
• swelling and redness along a vein
• red raised skin rash which may be itchiness
• pain, burning, swelling or inflammation at the injection site
• increase in a type of white blood cell (eosinophilia) or in the number of cells that
help the blood to clot
• increase in liver enzymes.
Uncommon: may affect up to 1 in 100 people:
• inflammation of the gut which can cause pain or diarrhoea which may contain
• thrush – fungal infections in the mouth or vagina
• headache
• dizziness
• stomach ache
• feeling sick or being sick
• fever and chills
• decrease in the number of white blood cells or in the number of blood platelets
(cells that help the blood to clot), increase in the level of urea, urea nitrogen or
serum creatinine in the blood.
Very rare: may affect up to 1 in 10,000 people:
• inflammation or failure of the kidneys.

Solutions range in colour from light yellow to amber depending on concentration,
diluent and storage conditions used. Within the stated recommendations, the
product potency is not adversely affected by such colour variation.
Ceftazidime is compatible with:
• Water for injection
• Sodium chloride solution 9 mg/ml (0.9 %) solution for injection
• Glucose 50 mg/ml (5 %)
• Glucose 50 mg/ml (5 %) in 0.9% sodium chloride injection
Ceftazidime may be constituted for intramuscular use with 1% lidocaine solution
for injection.
1 g, 2 g, 3 g Powder for solution for injection or infusion:
Preparation of solutions for bolus injection
1. Insert the syringe needle through the vial closure and inject the recommended
volume of diluent. Remove the syringe needle.
2. Shake to dissolve: carbon dioxide is released and a clear solution will be obtained
in about 1 to 2 minutes.
3. Invert the vial. With the syringe plunger fully depressed, insert the needle through
the vial closure and withdraw the total volume of solution into the syringe (the
pressure in the vial may aid withdrawal). Ensure that the needle remains within
the solution and does not enter the head space. The withdrawn solution may
contain small bubbles of carbon dioxide, they may be disregarded.

Not known: frequency cannot be estimated from the available data:
• pins and needles
• unpleasant taste in the mouth
• yellowing of the whites of the eyes or skin
• red blood cells destroyed too quickly, increase in a certain type of white blood
cells, severe decrease in the number of white blood cells.
If you get any side effects talk to your doctor or nurse. This includes any possible
side effect not listed in this leaflet.
5. How to store CEFTAZIDIME
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and
carton after EXP. The expiry date refers to the last day of that month.
Store below 25°C.
Keep vial in the original outer carton.
Reconstituted/diluted solutions should be used immediately.
Discard any unused solution.
Do not throw away any medicines via wastewater. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the
6. Contents of the pack and other information
What Ceftazidime contains
The active substance ceftazidime as ceftazidime pentahydrate.
One vial of 1 g Powder for solution for injection or infusion contains ceftazidime
pentahydrate, equivalent to 1 g of ceftazidime.
The other ingredients are:
Sodium carbonate, anhydrous (E500)
What Ceftazidime looks like and contents of the pack
The reconstituted solution is light yellow to amber in colour. The colour depends
on the amount of liquid used to dissolve the powder and the concentration of
ceftazidime in the reconstituted solution. The antibiotic effect of the solution is not
affected by its colour.
1 g, 2 g and 3 g Powder for solution for injection or infusion:
Ceftazidime is available as Powder for solution for injection or infusion. The powder
is white to almost white. The powder is supplied as a single dose vial packed in a
carton box. Each carton box contains 10 vials.
Marketing Authorisation Holder
Stragen UK Limited, Castle Court, 41 London Road, Reigate, Surrey RH2 9RJ
Mitim S.R.L., Via Cacciamali 34/38, 25125 Brescia, Italy
This medicinal product is authorised in the Member States of the EEA under the
following names:
Czech Republic, Denmark,
Finland, Norway:
Ceftazidim Stragen
Ireland, United Kingdom:
Ceftazidim Stragen 1 g

Pulver zur Herstellung einer Injektionslösung/


This leaflet was last revised
in October 2012

These solutions may be given directly into the vein or introduced into the tubing of
a giving set if the patient is receiving parenteral fluids.
1 g, 2 g, 3 g Powder for solution for injection or infusion:
Preparation of solutions for i.v. infusion:
Prepare using a total of 50 ml (for 1 g and 2 g vials) and 75 ml (for 3 g vials) of
compatible diluent, added in TWO stages as below.
1. Introduce the syringe needle through the vial closure and inject 10 ml of the
diluent for the 1 g and 2 g vials, and 15 ml for the 3 g vial.
2. Withdraw the needle and shake the vial to give a clear solution.
3. Do not insert a gas relief needle until the product has dissolved. Insert a gas relief
needle through the vial closure to relieve the internal pressure.
4. Add a further 40 ml of diluent for the 1 g and 2 g vials and 60 ml for the 3 g vial.
Remove the vent needle.
5. Administer by intravenous infusion over 15 to 30 min. Additional pressure that may
develop in the vial especially after storage should be relieved prior to
administration to the patient
NOTE: To preserve product sterility, it is important that the gas relief needle is not
inserted through the vial closure before the product has dissolved.
The solution should only be used if the solution is clear and free from particles.

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.